|
시장보고서
상품코드
2026019
IFx 2.0 : 판매 예측 및 시장 규모(2034년)IFx 2.0 Sales Forecast, and Market Size Analysis - 2034 |
||||||
DelveInsight
IFx 2.0의 성장을 이끄는 주요 요인들
1. 체크포인트 억제제 내성을 타겟으로 하는 새로운 작용기전
- IFx-2.0은 펨브롤리주맙과 같은 체크포인트 억제제(CPI)에 대한 1차 내성을 극복하도록 설계된 자연면역 작용제/국소 암 백신입니다.
- 종양 내 투여 후 전신적인 항종양 면역반응(압스코팔 효과)을 유도합니다.
성장에 대한 시사점:
- 미충족 의료 수요에 대응: 약 40-50%의 환자가 1차 선택 체크포인트 억제제에 반응하지 않는 경우가 있습니다.
- 경쟁약물이 아닌 병용요법을 가능하게 하는 치료제로서 강력한 포지셔닝을 확립하고 있습니다.
2. 초기 임상시험에서 강력한 효능의 징후
- 진행성/전이성 메르켈세포암(MCC)을 대상으로 한 임상 Ib상 시험:
- CPI 내성 환자에서 전체 반응률(ORR) : 63%(완전반응 2례, 부분반응 5례)
- 최대 23-33개월 지속되는 효과
- 추가 데이터:
- 항 PD(L)-1 요법을 재투여한 특정 하위 그룹에서 최대 80%의 반응률을 보였습니다.
3. 3상 시험으로 전환(승인 신청 단계의 자산)
- 2025년 FDA의 특별 프로토콜 평가(SPA)에 따라 임상 3상 조기 승인 시험을 시작했습니다.
- 주요 평가항목: 신속 승인에 적합한 전체 연주 효과율(ORR)
성장에 대한 시사점:
- 후기 개발 단계로의 전환에 따라 다음이 크게 증가했습니다.
- 사업화 가능성
- 단기적 가치의 전환점
4. 표준치료(KEYTRUDA 기반 치료)와의 병용요법
- 임상 3상에서는 MCC 1차 치료제로서 IFx-2.0+펨브롤리주맙과 펨브롤리주맙 단독요법을 비교 평가합니다.
성장에 대한 시사점:
- 300억 달러 이상의 블록버스터 치료제 기반 활용
- 승인되면 도입 가속화
- 기존 치료 패러다임에 쉽게 통합 가능
5. 희귀질환치료제 지정 및 규제상 우대 조치
- 흑색종에 대해 FDA로부터 희귀질환 치료제 지정(2026년)을 획득하였습니다.
주요 장점:
- 시장 독점권(미국에서는 7년)
- 수수료 감면 및 개발 인센티브
6. 여러 종양 유형에 걸친 플랫폼으로서의 가능성
- 대상 질환:
- 메르켈세포암(주요 적응증)
- 피부 편평상피암
- 악성 흑색종
- 시험에는 CPI 내성 그룹과 치료받지 않은 그룹이 모두 포함되었습니다.
IFx 2.0의 최근 동향
- 2026년 2월, 투휴라 바이오사이언스는 FDA 희귀질환 치료제 개발실이 IIB-IV기 피부 흑색종 치료제로 IFx-2.0에 희귀질환 치료제 지정(ODD)을 부여했다고 발표했습니다.
- 2025년 6월, TuHURA Biosciences는 Moffitt Cancer Center가 2025년 미국임상종양학회(ASCO) 연례총회에서 회사가 계획하고 있는 임상 3상 신속 승인 시험에 대한 '진행 중인' 포스터를 발표했다고 밝혔습니다. 진행 중인 시험' 포스터를 발표했다고 밝혔습니다.
이 보고서는 미국, EU4(독일, 프랑스, 이탈리아, 이탈리아, 스페인, 영국, 일본 등 주요 7개국(미국, EU4, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에서 IFx 2.0과 메르켈세포암, 기저세포암, 악성 흑색종, 편평상피암 등 잠재적 적응증에 대한 종합적인 인사이트를 제공합니다. 이 보고서는 2020년부터 2034년까지 주요 7개국 시장에서 IFx 2.0의 기존 사용 현황, 잠재적 적응증 진입 전망, 시장 성과에 대한 상세한 분석과 함께 IFx 2.0의 잠재적 적응증에 대한 상세한 설명을 제공합니다. 또한 IFx 2.0의 매출 예측, 작용기전(MoA), 용량 및 투여방법, 규제 마일스톤을 포함한 연구개발, 기타 활동, 미래 시장 평가, SWOT 분석, 애널리스트 견해, 경쟁사 개요, 각 적응증별 기타 신흥 치료제 개요, 시장을 이끄는 요인을 분석했습니다. 시장을 주도하는 요인에 대해서도 분석했습니다.
자주 묻는 질문
목차
제1장 보고서 개요
제2장 IFx 2.0 개요 : 메르켈 세포암, 기저세포암, 악성 흑색종, 편평상피암 등의 잠재적 적응증
제3장 IFx 2.0 : 경쟁 구도(출시 치료제)
제4장 IFx 2.0 : 경쟁 구도(후기 개발 단계 치료제)
제5장 IFx 2.0 : 시장 평가
제6장 IFx 2.0 : SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight에 대해
제12장 보고서 구입 옵션
LSH 26.05.19Key Factors Driving IFx 2.0 Growth
1. Novel mechanism targeting checkpoint inhibitor resistance
- IFx-2.0 is an innate immune agonist / in situ cancer vaccine designed to overcome primary resistance to checkpoint inhibitors (CPIs) such as pembrolizumab.
- It induces systemic anti-tumor immune responses (abscopal effect) after intratumoral injection.
Growth implication:
- Addresses a major unmet need: ~40-50% of patients do not respond to first-line checkpoint inhibitors.
- Strong positioning as a combination-enabling therapy, not a competitor.
2. Strong early clinical efficacy signals
- Phase Ib trial in advanced/metastatic Merkel cell carcinoma (MCC):
- Overall response rate (ORR): 63% (2 CR, 5 PR) in CPI-refractory patients
- Durable responses lasting up to 23-33 months
- Additional data:
- Up to 80% response rates in certain subgroups when rechallenged with anti-PD(L)-1 therapy
3. Advancement into Phase III (registration-stage asset)
- Phase III accelerated approval trial initiated in 2025 under FDA Special Protocol Assessment (SPA).
- Primary endpoint: Overall Response Rate (ORR) suitable for accelerated approval.
Growth implication:
- Late-stage development significantly increases:
- Probability of commercialization
- Near-term value inflection
4. Combination with standard-of-care (KEYTRUDA backbone)
- Phase III evaluates IFx-2.0 + pembrolizumab vs pembrolizumab alone in first-line MCC.
Growth implication:
- Leveraging a $30B+ blockbuster therapy backbone ->
- Faster adoption if approved
- Easier integration into existing treatment paradigms
5. Orphan Drug Designation and regulatory advantages
- Granted FDA Orphan Drug Designation (2026) for melanoma.
Benefits include:
- Market exclusivity (7 years in the US)
- Fee reductions and development incentives
6. Platform potential across multiple tumor types
- Studied in:
- Merkel cell carcinoma (lead indication)
- Cutaneous squamous cell carcinoma
- Melanoma
- Trials include both checkpoint inhibitor-resistant and naive populations
IFx 2.0 Recent Developments
- In February 2026, TuHURA Biosciences announced that the US Food and Drug Administration's (FDA) Office of Orphan Products Development had granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.
- In June 2025, TuHURA Biosciences announced that Moffitt Cancer Center presented a Trial in Progress poster of the Company's planned Phase III accelerated approval trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
"IFx 2.0 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of IFx 2.0 for potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer in the 7MM. A detailed picture of IFx 2.0's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the IFx 2.0 for potential indications. The IFx 2.0 market report provides insights about IFx 2.0's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IFx 2.0 performance, future market assessments inclusive of the IFx 2.0 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IFx 2.0 sales forecasts, along with factors driving its market.
IFx 2.0 Drug Summary
IFx 2.0 is an investigational, first-in-class DNA plasmid-based immunotherapy developed by Inhibikase Therapeutics (via its subsidiary IFx Biotechnologies) for the treatment of autoimmune and inflammatory diseases. The therapy is designed to activate Toll-like receptor 9 (TLR9), a key component of the innate immune system, by introducing a non-coding plasmid DNA that stimulates a controlled immune response. Unlike traditional immunosuppressive therapies, IFx-2.0 aims to reprogram immune signaling pathways to restore immune tolerance and reduce chronic inflammation. It is being investigated primarily for dermatologic conditions such as Vitiligo, where localized administration (typically via intradermal injection) may promote repigmentation by modulating immune-mediated melanocyte destruction. Early-stage studies have shown encouraging signs of immune activation and clinical response, supporting its potential as a novel disease-modifying therapy in autoimmune indications. The report provides IFx 2.0's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the IFx 2.0 Market Report
The report provides insights into:
- A comprehensive product overview including the IFx 2.0 MoA, description, dosage and administration, research and development activities in potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer.
- Elaborated details on IFx 2.0 regulatory milestones and other development activities have been provided in IFx 2.0 market report.
- The report also highlights IFx 2.0's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
- The IFx 2.0 market report also covers the patents information, generic entry and impact on cost cut.
- The IFx 2.0 market report contains current and forecasted IFx 2.0 sales for potential indications till 2034.
- Comprehensive coverage of the late-stage emerging therapies for respective indications.
- The IFx 2.0 market report also features the SWOT analysis with analyst views for IFx 2.0 in potential indications.
Methodology:
The IFx 2.0 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
IFx 2.0 Analytical Perspective by DelveInsight
- In-depth IFx 2.0 Market Assessment
This IFx 2.0 sales market forecast report provides a detailed market assessment of IFx 2.0 for potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IFx 2.0 sales data uptil 2034.
- IFx 2.0 Clinical Assessment
The IFx 2.0 market report provides the clinical trials information of IFx 2.0 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
IFx 2.0 Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
IFx 2.0 Market Potential & Revenue Forecast
- Projected market size for the IFx 2.0 and its key indications
- Estimated IFx 2.0 sales potential (IFx 2.0 peak sales forecasts)
- IFx 2.0 Pricing strategies and reimbursement landscape
IFx 2.0 Competitive Intelligence
- Number of competing drugs in development (pipeline analysis)
- IFx 2.0 Market positioning compared to existing treatments
- IFx 2.0 Strengths & weaknesses relative to competitors
IFx 2.0 Regulatory & Commercial Milestones
- IFx 2.0 Key regulatory approvals & expected launch timelines
- Commercial partnerships, licensing deals, and M&A activity
IFx 2.0 Clinical Differentiation
- IFx 2.0 Efficacy & safety advantages over existing drugs
- IFx 2.0 Unique selling points
IFx 2.0 Market Report Highlights
- In the coming years, the IFx 2.0 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
- The IFx 2.0 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IFx 2.0's dominance.
- Other emerging products for Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer are expected to give tough market competition to IFx 2.0 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IFx 2.0 in potential indications.
- Analyse IFx 2.0 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
- Our in-depth analysis of the forecasted IFx 2.0 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IFx 2.0 in potential indications.
Key Questions:
- What is the class of therapy, route of administration and mechanism of action of IFx 2.0? How strong is IFx 2.0's clinical and commercial performance?
- What is IFx 2.0's clinical trial status in each individual indications such as Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IFx 2.0 Manufacturers?
- What are the key designations that have been granted to IFx 2.0 for potential indications? How are they going to impact IFx 2.0's penetration in various geographies?
- What is the current and forecasted IFx 2.0 market scenario for potential indications? What are the key assumptions behind the forecast?
- What are the current and forecasted sales of IFx 2.0 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
- What are the other emerging products available and how are these giving competition to IFx 2.0 for potential indications?
- Which are the late-stage emerging therapies under development for the treatment of potential indications?
- How cost-effective is IFx 2.0? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. IFx 2.0 Overview in potential indication like Merkel cell carcinoma, Basal cell cancer, Malignant melanoma, and Squamous cell cancer
- 2.1. Product Detail
- 2.2. IFx 2.0 Clinical Development
- 2.2.1. IFx 2.0 Clinical studies
- 2.2.2. IFx 2.0 Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
3. IFx 2.0 Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging IFx 2.0 Therapies)
5. IFx 2.0 Market Assessment
- 5.1. IFx 2.0 Market Outlook in potential indications
- 5.2. 7MM Analysis
- 5.2.1. IFx 2.0 Market Size in the 7MM for potential indications
- 5.3. Country-wise Market Analysis
- 5.3.1. IFx 2.0 Market Size in the United States for potential indications
- 5.3.2. IFx 2.0 Market Size in Germany for potential indications
- 5.3.3. IFx 2.0 Market Size in France for potential indications
- 5.3.4. IFx 2.0 Market Size in Italy for potential indications
- 5.3.5. IFx 2.0 Market Size in Spain for potential indications
- 5.3.6. IFx 2.0 Market Size in the United Kingdom for potential indications
- 5.3.7. IFx 2.0 Market Size in Japan for potential indications
6. IFx 2.0 SWOT Analysis
7. Analysts' Views
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
